Evaluation Amyotrophic Lateral Sclerosis: Recent Advances in Diagnosis and Emerging Treatment Options Evaluation HMP Education would appreciate your feedback on the quality and impact of this activity.Please answer the following questions, some of which include a 5-point Likert scale (5 = strongly agree/excellent/great deal; 1 = strongly disagree/poor/very little). To what extent are you able to better achieve each of the following learning objectives? Summarize the underlying pathophysiology of ALS 5 4 3 2 1 Identify challenges and opportunities in the accurate and early diagnosis of ALS 5 4 3 2 1 Evaluate the efficacy and safety of currently approved disease - modifying and symptom - based therapies for patients with ALS 5 4 3 2 1 Implement multidisciplinary and patient - centric management strategies for patients with ALS 5 4 3 2 1 Please rate the faculty on their knowledge, expertise, and teaching ability (5= excellent, 3 = good, 1 = poor). Terry Heiman-Patterson, MD 5 4 3 2 1 Please rate the following components relating to this activity: Content 5 4 3 2 1 Relevance to your practice 5 4 3 2 1 Educational format 5 4 3 2 1 Audience-participation portions (eg., Q&A, polling, pre/post-testing) 5 4 3 2 1 Resources and/or other materials supporting the activity 5 4 3 2 1 Overall 5 4 3 2 1 Therapeutic recommendations presented in this activity did not encourage inappropriate or excessive use of products/devices. Agree Disagree How many patients with ALS do you see during a typical month? 0 patients 1-10 patients 11-20 patients 21-30 patients More than 30 patients Do you feel like there were any new data presented? Yes, please specify: No Did you learn anything new? Yes, please specify: No Did you gain confidence on the new information? Yes, why? No, why? Did this program include opportunities to learn as a part of a healthcare team? Yes, please specify: No As lower motor neurons degenerate, which of the following is likely to occur? Fasciculation Hyperreflexia Pseudobulbar affect Spasticity ALS overlaps both clinically and pathologically with which of the following? Alzheimer’s disease Frontotemporal dementia Lewy body dementia Parkinsonism According to results from the CENTAUR randomized clinical trial, which of the following pharmacotherapies was found to be effective in slowing ALS progression? Edaravone Mematine + donepezil Paroxetine Sodium phenylbutyrate + taurursodiol How frequently will you now implement ALS screening practices for at-risk patient populations? Always Often Sometimes Rarely Do you intend to make any additional changes to your practice as a result of information gained from this activity? Please be specific. Yes, please describe: No What challenges or barriers outside of your control may prevent you from changing your practice? Adverse effects of available treatments Affordability/cost Institutional policy Insurance/formulary Lack of patient education/engagement Limited resources/time Need more information on optimal management strategies Outdated or unclear guidelines Patient adherence Other: How might future activities help you address those barriers? 255 characters max The information presented in this activity did not serve to advance a proprietary interest of any commercial entity. Agree Disagree Based on my participation in this activity, I anticipate I will more often (select all that apply): Utilize newer therapies that have been found to slow down ALS progression Make informed recommendations for ALS therapies based on individual patient profiles and the latest available clinical evidence Develop patient-centered management plans that underscore the importance of shared decision- making and patient activation Implement strategies to help overcome common barriers to care, including early diagnosis and patient/caregiver education on appropriate ALS care Integrate evidence-based guidelines for ALS management while supporting the translation of clinical evidence into practice Employ multidisciplinary care strategies for the management of patients with ALS Other, please specify: Previous
